Notice2023-27112
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 11, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 236 (Monday, December 11, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 236 (Monday, December 11, 2023)]
[Notices]
[Pages 85895-85896]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-27112]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Brian Bailey, Ph.D.; 240-669-5128 or
301-201-9217; <a href="/cdn-cgi/l/email-protection#4e2c2c2f27222b370e232f27226020272660292138"><span class="__cf_email__" data-cfemail="583a3a3931343d21183539313476363130763f372e">[email protected]</span></a>. Licensing information may be
obtained by communicating with the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Enhanced Immune Response With Stabilized Norovirus VLPs: A Next-
Generation Vaccine Approach
Description of Technology: This technology includes a novel
advancement in developing vaccines targeting norovirus, tailored
specifically for a more robust and effective response. It centers
around an improved version of Virus-Like Particles (VLPs) uniquely
engineered for greater stability and efficacy. These enhanced VLPs are
designed to remain intact even when faced with the body's immune
responses, overcoming a key limitation of previous vaccine designs.
This stability is crucial in ensuring the vaccine's effectiveness,
particularly in individuals with more robust immune systems who have
shown limited response to traditional vaccines. Additionally, the
modified VLPs are likely more resistant to degradation, making them a
more reliable and durable solution in vaccination campaigns. This
innovation could be a significant step in offering a more effective
vaccine option for widespread use.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Enhanced Norovirus Vaccination: Specially designed to
improve the effectiveness of vaccines against norovirus, particularly
in individuals with previously low response rates to traditional
vaccines.
<bullet> Broad-Scale Immunization Programs: Suitable for large-
scale public health initiatives due to its increased
[[Page 85896]]
stability and durability, potentially reducing the frequency of booster
shots.
<bullet> Platform for Future Vaccine Development: The stabilization
techniques used in this technology could be applied to other vaccine
formulations, paving the way for more robust and effective vaccines
against various pathogens.
Competitive Advantages:
<bullet> Provides enhanced stability and efficacy in norovirus VLP
vaccines, ensuring effectiveness even in individuals with strong immune
responses who have previously shown limited vaccine response.
<bullet> Its innovative design increases the VLPs' resistance to
degradation, offering a more durable and reliable option for large-
scale immunization programs.
Development Stage:
<bullet> Pre-Clinical.
Inventors: Lisa Lindesmith, Ralph Baric, George Georgiou, Peter
Kwong, Raffaello Veradi, Yaroslav Tsybovsky, Jason Gorman, Gwo-Yu
Chuang and Li Ou, all of NIAID.
Publications: Lu, Yuan et al. ``Assessing sequence plasticity of a
virus-like nanoparticle by evolution toward a versatile scaffold for
vaccines and drug delivery.'' Proceedings of the National Academy of
Sciences of the United States of America vol. 112,40 (2015): 12360-5.
DOI: 10.1073/pnas.1510533112 at <a href="https://doi.org/10.1073/pnas.1510533112">https://doi.org/10.1073/pnas.1510533112</a>; Porta, Claudine et al. ``Rational engineering of
recombinant picornavirus capsids to produce safe, protective vaccine
antigen.'' PLoS pathogens vol. 9,3 (2013): e1003255. DOI: 10.1371/
journal.ppat.1003255 at <a href="https://doi.org/10.1371/journal.ppat.1003255">https://doi.org/10.1371/journal.ppat.1003255</a>;
Mateo, Roberto et al. ``Engineering viable foot-and-mouth disease
viruses with increased thermostability as a step in the development of
improved vaccines.'' Journal of virology vol. 82,24 (2008): 12232-40.
DOI: 10.1128/JVI.01553-08 at <a href="https://doi.org/10.1128/jvi.01553-08">https://doi.org/10.1128/jvi.01553-08</a>;
Bertolotti-Ciarlet, Andrea et al. ``Structural requirements for the
assembly of Norwalk virus-like particles.'' Journal of virology vol.
76,8 (2002): 4044-55. DOI: 10.1128/jvi.76.8.4044-4055.2002 at <a href="https://doi.org/10.1128/jvi.76.8.4044-4055.2002">https://doi.org/10.1128/jvi.76.8.4044-4055.2002</a>; Prasad, B V et al. ``X-ray
crystallographic structure of the Norwalk virus capsid.'' Science (New
York, N.Y.) vol. 286,5438 (1999): 287-90. DOI: 10.1126/
science.286.5438.287 at <a href="https://doi.org/10.1126/science.286.5438.287">https://doi.org/10.1126/science.286.5438.287</a>.
Intellectual Property: HHS Reference No. E-178-2019-0; U.S.
Provisional Patent Application No. 63/091,824, filed on October 14,
2020; PCT Patent Application No. PCT/US2021/55018, filed October 14,
2021; U.S. National Stage patent application, U.S. 18/031,602, filed
April 12, 2023.
Licensing Contact: To license this technology, please contact Brian
Bailey, Ph.D.; 240-669-5128 or 301-201-9217; <a href="/cdn-cgi/l/email-protection#b6d4d4d7dfdad3cff6dbd7dfda98d8dfde98d1d9c0"><span class="__cf_email__" data-cfemail="bfddddded6d3dac6ffd2ded6d391d1d6d791d8d0c9">[email protected]</span></a>, and
reference E-178-2019.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Brian Bailey, Ph.D.; 240-669-5128 or 301-
201-9217; <a href="/cdn-cgi/l/email-protection#a9cbcbc8c0c5ccd0e9c4c8c0c587c7c0c187cec6df"><span class="__cf_email__" data-cfemail="f89a9a9991949d81b895999194d6969190d69f978e">[email protected]</span></a>.
Dated: December 5, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-27112 Filed 12-8-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 11, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.